What is Avicena?
Avicena operates at the intersection of advanced algorithmic processing and medical device engineering. The company specializes in developing noninvasive tools designed to assess cardiovascular health with high precision at the point of care. By providing physicians and patients with actionable, next-generation data analysis, Avicena addresses the critical need for early detection of previously undiagnosed cardiovascular conditions. This market position is particularly vital as healthcare systems shift toward proactive, data-driven patient management models that prioritize early intervention to reduce long-term morbidity and healthcare costs.
How much funding has Avicena raised?
Avicena has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Avicena
PPP
Public-Private Partnership
What's next for Avicena?
Following this late-stage financing, Avicena is expected to scale its operational footprint and expand its clinical validation studies. The strategic deployment of this capital will likely focus on enhancing the scalability of its diagnostic devices and deepening the integration of its analytical software within existing hospital infrastructure. As the company matures, the focus will shift toward broader commercial adoption and the potential expansion of its diagnostic suite to cover a wider array of cardiovascular pathologies, solidifying its role as a key player in the digital health ecosystem.
See full Avicena company page
